Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain

The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in 2016, compared with $21.7 billion in 2011, according to Small-Molecule Targeted Cancer Therapies: World Market 2013-2023, published by business information provider Visiongain. The work analyses the USA, Japan, Germany, France, the UK, Spain, Italy (EU5), India and China.

Visiongain forecasts that the overall market for small-molecule targeted cancer therapies will grow steadily to 2023. Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate that drug market. The R&D pipeline holds great promise. Also, in most countries, high demand exists for newer, better cancer treatments. There remain many commercial opportunities for small-molecule cancer treatments from 2013 to 2023, the study concludes.

Targeted cancer therapies block the growth and spread of cancer by interfering with molecules involved in tumor growth and progression. Unlike antibody therapies, small-molecule targeted cancer drugs pass through cell membranes to reach targets inside cells.